PURE Bioscience Statistics
Total Valuation
PURE Bioscience has a market cap or net worth of 9.06 million. The enterprise value is 14.58 million.
| Market Cap | 9.06M |
| Enterprise Value | 14.58M |
Important Dates
The next estimated earnings date is Thursday, October 29, 2026.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
PURE Bioscience has 130.02 million shares outstanding. The number of shares has decreased by -0.20% in one year.
| Current Share Class | 130.02M |
| Shares Outstanding | 130.02M |
| Shares Change (YoY) | -0.20% |
| Shares Change (QoQ) | -0.94% |
| Owned by Insiders (%) | 35.50% |
| Owned by Institutions (%) | n/a |
| Float | 83.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.74 |
| PB Ratio | -1.55 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.02 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.42
| Current Ratio | 0.42 |
| Quick Ratio | 0.34 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.91 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -91.59% |
| Return on Invested Capital (ROIC) | -322.34% |
| Return on Capital Employed (ROCE) | 91.41% |
| Weighted Average Cost of Capital (WACC) | 4.98% |
| Revenue Per Employee | 201,833 |
| Profits Per Employee | -183,750 |
| Employee Count | 12 |
| Asset Turnover | 1.85 |
| Inventory Turnover | 5.49 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.33% in the last 52 weeks. The beta is 0.16, so PURE Bioscience's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | -33.33% |
| 50-Day Moving Average | 0.07 |
| 200-Day Moving Average | 0.07 |
| Relative Strength Index (RSI) | 50.51 |
| Average Volume (20 Days) | 18,930 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.11 |
Income Statement
In the last 12 months, PURE Bioscience had revenue of 2.42 million and -2.21 million in losses. Loss per share was -0.02.
| Revenue | 2.42M |
| Gross Profit | 1.43M |
| Operating Income | -1.92M |
| Pretax Income | -2.21M |
| Net Income | -2.21M |
| EBITDA | -1.91M |
| EBIT | -1.92M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 983,000 in cash and 6.50 million in debt, with a net cash position of -5.51 million or -0.04 per share.
| Cash & Cash Equivalents | 983,000 |
| Total Debt | 6.50M |
| Net Cash | -5.51M |
| Net Cash Per Share | -0.04 |
| Equity (Book Value) | -5.84M |
| Book Value Per Share | -0.04 |
| Working Capital | -2.11M |
Cash Flow
| Operating Cash Flow | -1.78M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 2,000 |
| Net Borrowing | 1.22M |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 58.84%, with operating and profit margins of -79.11% and -91.04%.
| Gross Margin | 58.84% |
| Operating Margin | -79.11% |
| Pretax Margin | -91.04% |
| Profit Margin | -91.04% |
| EBITDA Margin | -79.03% |
| EBIT Margin | -79.11% |
| FCF Margin | n/a |
Dividends & Yields
PURE Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.20% |
| Shareholder Yield | 0.20% |
| Earnings Yield | -24.33% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 15, 2012. It was a reverse split with a ratio of 0.125.
| Last Split Date | Aug 15, 2012 |
| Split Type | Reverse |
| Split Ratio | 0.125 |
Scores
PURE Bioscience has an Altman Z-Score of -130.06 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -130.06 |
| Piotroski F-Score | 3 |